Assessing Plasma APLP1 for the Progression of Parkinson's Disease: Insights from HSPD and PPMI Cohorts

IF 7.4 1区医学 Q1 CLINICAL NEUROLOGY

Movement Disorders Pub Date : 2025-02-19 DOI:10.1002/mds.30154

You Ni MD, Ya-Nan Yin PhD, Wen-Bo Yu MD PhD, Yi-Qi Liu MD PhD, Jue Zhao MD, Yu-Chen Yan MD, Wan-Bing Zhao MD, Yi-Lin Tang MD PhD, Yi-Min Sun MD PhD, Feng-Tao Liu MD PhD, Peng Ran PhD, Jian-Jun Wu MD PhD, Chen Ding PhD, Jian Wang MD PhD

{"title":"Assessing Plasma APLP1 for the Progression of Parkinson's Disease: Insights from HSPD and PPMI Cohorts","authors":"You Ni MD, Ya-Nan Yin PhD, Wen-Bo Yu MD PhD, Yi-Qi Liu MD PhD, Jue Zhao MD, Yu-Chen Yan MD, Wan-Bing Zhao MD, Yi-Lin Tang MD PhD, Yi-Min Sun MD PhD, Feng-Tao Liu MD PhD, Peng Ran PhD, Jian-Jun Wu MD PhD, Chen Ding PhD, Jian Wang MD PhD","doi":"10.1002/mds.30154","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Amyloid precursor-like protein 1 (APLP1) is involved in pathological α-synuclein transmission, but its role in Parkinson's disease (PD) progression has not been explored.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>This study investigates APLP1 as a potential predictor for motor and cognitive deterioration in PD.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Plasma APLP1 levels were measured in PD patients from the Huashan Hospital for Parkinson's Disease (HSPD) and Parkinson's Disease Progression Markers Initiative (PPMI) cohorts. A total of 916 participants were recruited in the HSPD cohort, and 171 participants were in the PPMI cohort. Longitudinal analysis examined the association between baseline APLP1 levels and PD progression.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A significant increase in APLP1 levels was observed in PD patients compared to healthy controls. Longitudinal analysis showed that patients with elevated baseline APLP1 levels experienced faster motor deterioration in HSPD cohort (HR = 3.627, <i>P</i> < 0.0001).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The data indicate that APLP1 is associated with the progression of PD, potentially offering a measurable indicator of disease progression. © 2025 International Parkinson and Movement Disorder Society.</p>\n </section>\n </div>","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"40 5","pages":"969-974"},"PeriodicalIF":7.4000,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Movement Disorders","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/mds.30154","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Amyloid precursor-like protein 1 (APLP1) is involved in pathological α-synuclein transmission, but its role in Parkinson's disease (PD) progression has not been explored.

Objective

This study investigates APLP1 as a potential predictor for motor and cognitive deterioration in PD.

Methods

Plasma APLP1 levels were measured in PD patients from the Huashan Hospital for Parkinson's Disease (HSPD) and Parkinson's Disease Progression Markers Initiative (PPMI) cohorts. A total of 916 participants were recruited in the HSPD cohort, and 171 participants were in the PPMI cohort. Longitudinal analysis examined the association between baseline APLP1 levels and PD progression.

Results

A significant increase in APLP1 levels was observed in PD patients compared to healthy controls. Longitudinal analysis showed that patients with elevated baseline APLP1 levels experienced faster motor deterioration in HSPD cohort (HR = 3.627, P < 0.0001).

Conclusions

查看原文本刊更多论文

评估血浆APLP1对帕金森病进展的影响：来自HSPD和PPMI队列的见解

背景：淀粉样蛋白前体样蛋白1 （APLP1）参与病理性α-突触核蛋白传递，但其在帕金森病（PD）进展中的作用尚未被探索。目的：本研究探讨APLP1作为PD患者运动和认知功能恶化的潜在预测因子。方法：测量华山帕金森病医院（HSPD）和帕金森病进展标志物倡议（PPMI）队列PD患者血浆APLP1水平。HSPD组共招募了916名参与者，PPMI组共招募了171名参与者。纵向分析检测了基线APLP1水平与PD进展之间的关系。结果：与健康对照组相比，PD患者的APLP1水平显著升高。纵向分析显示，在HSPD队列中，APLP1基线水平升高的患者运动功能恶化更快（HR = 3.627， P）。结论：数据表明，APLP1与PD的进展相关，可能为疾病进展提供可测量的指标。©2025国际帕金森和运动障碍学会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Movement Disorders 医学-临床神经学

CiteScore

13.30

自引率

8.10%

发文量

371

审稿时长

12 months

期刊介绍： Movement Disorders publishes a variety of content types including Reviews, Viewpoints, Full Length Articles, Historical Reports, Brief Reports, and Letters. The journal considers original manuscripts on topics related to the diagnosis, therapeutics, pharmacology, biochemistry, physiology, etiology, genetics, and epidemiology of movement disorders. Appropriate topics include Parkinsonism, Chorea, Tremors, Dystonia, Myoclonus, Tics, Tardive Dyskinesia, Spasticity, and Ataxia.